Search
Capmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigational[L13347] The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same … [A199122] This co-occurrence has made c-Met a desirable target in the treatment of NSCLC.
Isatuximab
go.drugbank.com/drugs/DB14811ApprovedInvestigational[L12099] It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma. … Following three consecutive years on the yearly "Antibodies to watch" list published in "mAb", a peer-reviewed scientific journal dedicated to antibody research,[A38676,A191826,A191829] isatuximab was
Categories: CD38 (Clusters of Differentiation 38) inhibitorsModafinil
go.drugbank.com/drugs/DB00745ApprovedInvestigationalModafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. … Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil.
Categories: Metabolic Side Effects of Drugs and SubstancesDiphenylguanidine
go.drugbank.com/drugs/DB14191ApprovedDiphenylguanidine is a complexing agent used in the detection of metals and organic bases and used as an accelerator in the vulcanization of rubber. It is found in some rubber products. … It is also a dermatological sensitizer and allergen. Sensitivity to diphenylguanidine may be identified with a clinical patch test.
International brands: Soxinol D, Nocceler DUstekinumab
go.drugbank.com/drugs/DB05679ApprovedInvestigational[A187349] It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. … including Wezlana,[L49071] Yesintek,[L52815] Selarsdi,[L52820] Otulfi,[L52825] and Pyzchiva[L52810] in the US, Jamteki (AVT04),[L49076] Steqeyma,[L52830] and Wezlana [L52073] in Canada, and Uzpruvo in the EU
Gestrinone
go.drugbank.com/drugs/DB11619ApprovedGestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group that is marketed in Europe, Australia, and Latin America, though not the United States or Canada, and … However, from 1982 this drug attracted increased interest due to significant therapeutic effects in the treatment endometriosis.
Categories: Sex Hormones and Modulators of the Genital SystemIvosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigational[A248745] It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma … [L48781] In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexFerrous asparto glycinate
go.drugbank.com/drugs/DB11169ApprovedFerrous asparto glycinate is an iron-amino acid chelate. It is available as a dietary supplement used in the treatment of iron deficiency and iron deficiency anemia.
Mixtures: Paire OB Plus DHA, OB Complete DHASonrotoclax
go.drugbank.com/drugs/DB18753ApprovedInvestigationallines of systemic therapy, including a BTK inhibitor. … Sonrotoclax is a selective, potent, small-molecule inhibitor of BCL-2, an antiapoptotic protein overexpressed in B-cell malignancies.
Pembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigationalIt was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. … [A7624] In the time since its initial approval, pembrolizumab has been granted approval in the treatment of a wide variety of cancers.